Addition of bevacizumab to conventional therapy improved progression-free survival in HER2-positive breast cancer
SAN ANTONIO — Data evaluated by an independent review committee revealed that the addition of bevacizumab to trastuzumab and docetaxel significantly improved progression-free survival in HER2-positive breast cancer, despite findings from an investig…